tbuckley/cabot-search huggingface dataset:
Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry
Authors: Diana P. Ruiz Genao, Gregorio Carretero, Raquel Rivera-Diaz, Jose Manuel Carrascosa, Antonio Sahuquillo-Torralba, Enrique Herrera-Acosta, Francisco José Gómez García, Esteban Daudén, Jose Luis López Estebaranz, Ignacio Garcia-Doval
Journal: British Journal of Dermatology (2022)

Journal Article Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry Get access Diana P. Ruiz Genao, Diana P. Ruiz Genao Departments of Dermatology Hospital Universitario Fundación Alcorcón Madrid https://orcid.org/0000-0003-1093-6411 Search for other works by this author on: Oxford Academic Google Scholar Gregorio Carretero, Gregorio Carretero Hospital Universitario Dr Negrín Las Palmas de Gran Canaria Gran Canaria Search for other works by this author on: Oxford Academic Google Scholar Raquel Rivera‐Diaz, Raquel Rivera‐Diaz Hospital Universitario 12 de Octubre Madrid https://orcid.org/0000-0002-4604-0724 Search for other works by this author on: Oxford Academic Google Scholar Jose Manuel Carrascosa, Jose Manuel Carrascosa Hospital Universitario Germans Trias i Pujol, Universitat Autónoma de Barcelona Badalona Barcelona Search for other works by this author on: Oxford Academic Google Scholar Antonio Sahuquillo‐Torralba, Antonio Sahuquillo‐Torralba Hospital la Fé de Valencia Valencia https://orcid.org/0000-0002-9354-7464 Search for other works by this author on: Oxford Academic Google Scholar Enrique Herrera‐Acosta, Enrique Herrera‐Acosta Hospital Clínico de Málaga Málaga Search for other works by this author on: Oxford Academic Google Scholar Francisco José Gómez García, Francisco José Gómez García Hospital Universitario Reina Sofia Córdoba Search for other works by this author on: Oxford Academic Google Scholar Esteban Daudén, Esteban Daudén Hospital Universitario de La Princesa Madrid https://orcid.org/0000-0002-0676-1260 Search for other works by this author on: Oxford Academic Google Scholar Jose Luis López Estebaranz, Jose Luis López Estebaranz Departments of Dermatology Hospital Universitario Fundación Alcorcón Madrid Search for other works by this author on: Oxford Academic Google Scholar Ignacio Garcia‐Doval, Ignacio Garcia‐Doval Complexo Hospitalario Universitario de Vigo VigoResearch Unit Fundación Academia Española de Dermatologia y Venereologia Madrid Spain https://orcid.org/0000-0002-6881-5260 Search for other works by this author on: Oxford Academic Google Scholar ... Show more the BIOBADADERM Study Group the BIOBADADERM Study Group Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 187, Issue 5, 1 November 2022, Pages 817–820, https://doi.org/10.1111/bjd.21763 Published: 01 November 2022
Genome-wide DNA hypermethylation opposes healing in patients with chronic wounds by impairing epithelial-mesenchymal transition
Authors: Kanhaiya Singh, Yashika Rustagi, Ahmed S. Abouhashem, Saba Tabasum, Priyanka Verma, Edward Hernandez, Durba Pal, Dolly K. Khona, Sujit K. Mohanty, Manishekhar Kumar, Rajneesh Srivastava, Poornachander R. Guda, Sumit S. Verma, Sanskruti Mahajan, Jackson A. Killian, Logan A. Walker, Subhadip Ghatak, Shomita S. Mathew-Steiner, Kristen E. Wanczyk, Sheng Liu, Jun Wan, Pearlly Yan, Ralf Bundschuh, Savita Khanna, Gayle M. Gordillo, Michael P. Murphy, Sashwati Roy, Chandan K. Sen
Journal: Journal of Clinical Investigation (2022)

An extreme chronic wound tissue microenvironment causes epigenetic gene silencing. An unbiased whole-genome methylome was studied in the wound-edge tissue of patients with chronic wounds. A total of 4,689 differentially methylated regions (DMRs) were identified in chronic wound-edge skin compared with unwounded human skin. Hypermethylation was more frequently observed (3,661 DMRs) in the chronic wound-edge tissue compared with hypomethylation (1,028 DMRs). Twenty-six hypermethylated DMRs were involved in epithelial-mesenchymal transition (EMT). Bisulfite sequencing validated hypermethylation of a predicted specific upstream regulator TP53. RNA-Seq analysis was performed to qualify findings from methylome analysis. Analysis of the downregulated genes identified the TP53 signaling pathway as being significantly silenced. Direct comparison of hypermethylation and downregulated genes identified 4 genes, ADAM17, NOTCH, TWIST1, and SMURF1, that functionally represent the EMT pathway. Single-cell RNA-Seq studies revealed that these effects on gene expression were limited to the keratinocyte cell compartment. Experimental murine studies established that tissue ischemia potently induces wound-edge gene methylation and that 5'-azacytidine, inhibitor of methylation, improved wound closure. To specifically address the significance of TP53 methylation, keratinocyte-specific editing of TP53 methylation at the wound edge was achieved by a tissue nanotransfection-based CRISPR/dCas9 approach. This work identified that reversal of methylation-dependent keratinocyte gene silencing represents a productive therapeutic strategy to improve wound closure.
ICM Editors' reply to a letter by Wiedermann “Institutional recommendation for the withdrawal of scientific articles from Joachim Boldt”
Authors: Giuseppe Citerio, Samir Jaber, Thomas Bein, Katherine Brown, Alain Combes, Audrey De Jong, Julie Helms, Geert Meyfroidt, Laveena Munshi, Marlies Ostermann, Pedro Póvoa, Otavio Ranzani, Claudio Sandroni, Manu Shankar-Hari, Velia Marta Antonini, Aoife Abbey
Journal: Intensive Care Medicine (2022)
Improvements in Hospital Adverse Event Rates
Authors: William V. Padula, Peter J. Pronovost
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Over-the-Counter Availability of Rescue Inhalers for Asthma
Authors: Kathleen R. May, John J. Oppenheimer, Stanley J. Szefler
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Newer Poxvirus Vaccine Is Recommended
Authors: Bridget M. Kuehn
Journal: JAMA (2022)

As monkeypox cases increased in the US and abroad, a report from the CDC’s Advisory Committee on Immunization Practices (ACIP) outlined data supporting the November 2021 decision to recommend JYNNEOS, a newer vaccine against monkeypox and smallpox, for individuals at risk of occupational exposure.
Sublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder—Reply
Authors: Sheldon H. Preskorn, Robert Risinger, Rishi Kakar
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multifocal Fibrosing Thyroiditis: an Under-recognized Mimicker of Papillary Thyroid Carcinoma
Authors: Agnese Orsatti, Antonio De Leo, Federico Chiarucci, Giulia Simoncini, Nadia Cremonini, Adele Fornelli, Luca Amorosa, Thais Maloberti, Dario de Biase, Giovanni Tallini
Journal: Endocrine Pathology (2022)

Abstract Multifocal fibrosing thyroiditis (MFT) is an enigmatic entity, characterized by multiple fibrotic scar-like lesions with a paucicellular fibrotic center surrounded by a cellular peripheral area with reactive-appearing follicular cell atypia and variable chronic inflammation. Although poorly recognized and likely underreported in surgical pathology, the entity is considered rare with only 65 cases to date–including the current one reported to expand on the preoperative findings of this under-recognized entity. The average age of the patients is 46.8 years (range 15–71 years), 94% are female, with female to male ratio of 15:1. Individual MFT lesions typically have a superficial location. The average number of fibrotic lesions is 15.4 (range 2–51 per MFT case). Their average size is 3.1 mm (range 0.4–15.1). MFT is a disorder of diseased thyroids, typically found postoperatively in glands removed for other reasons, such as chronic lymphocytic/Hashimoto thyroiditis (32.3%), follicular nodular disease (nodular hyperplasia) (30.1%), hyperthyroidism/diffuse hyperplasia (Graves disease) (9.2%). Intriguing is the association with papillary thyroid carcinoma–present in 38.5% of MFT cases, and particularly with sub-centimetric and multifocal papillary thyroid carcinoma, with which MFT can be confused. Cases where MFT is the only thyroid pathology (7.7%) can be preoperatively mistaken for papillary thyroid carcinoma, due to worrisome ultrasound (US) and cytologic features, both of which are here documented for the first time as a component of this article. Wider recognition of MFT and of its cytologic and ultrasound features at preoperative evaluation may reduce unnecessary thyroidectomies.
Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis
Authors: Yang Mai, Yaqi Ouyang, Mian Yu, Yujia Qin, Michael Girardi, W. Mark Saltzman, Emiliano Cocco, Chao Zhao, Liu Yu, Yizhen Jia, Lingyun Xiao, Liu Dou, Wenbin Deng, Yang Liu, Julin Xie, Yang Deng
Journal: Journal of Controlled Release (2022)
Indocarbocyanine nanoparticles extravasate and distribute better than liposomes in brain tumors
Authors: Irina V. Balyasnikova, Markella Zannikou, Guankui Wang, Yue Li, Joseph T. Duffy, Rebecca N. Levine, Maggie Seblani, Hanmant Gaikwad, Dmitri Simberg
Journal: Journal of Controlled Release (2022)
Mucosal vaccine delivery: A focus on the breakthrough of specific barriers
Authors: Mengwen Huang, Miaomiao Zhang, Hongbin Zhu, Xiaojiao Du, Jun Wang
Journal: Acta Pharmaceutica Sinica B (2022)

Mucosal vaccines can effectively induce an immune response at the mucosal site and form the first line of defense against microbial invasion. The induced mucosal immunity includes the proliferation of effector T cells and the production of IgG and IgA antibodies, thereby effectively blocking microbial infection and transmission. However, after a long period of development, the transformation of mucosal vaccines into clinical use is still relatively slow. To date, fewer than ten mucosal vaccines have been approved. Only seven mucosal vaccines against coronavirus disease 2019 (COVID-19) are under investigation in clinical trials. A representative vaccine is the adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by Chen and coworkers, which is currently in phase III clinical trials. The reason for the limited progress of mucosal vaccines may be the complicated mucosal barriers. Therefore, this review summarizes the characteristics of mucosal barriers and highlights strategies to overcome these barriers for effective mucosal vaccine delivery.
Effect of the Family-Centered Advance Care Planning for Teens with Cancer Intervention on Sustainability of Congruence About End-of-Life Treatment Preferences
Authors: Jennifer Susan Needle, Sarah Friebert, Jessica D. Thompkins, Daniel H. Grossoehme, Justin N. Baker, JiJi Jiang, Jichuan Wang, Maureen E. Lyon
Journal: JAMA Network Open (2022)

The effect of pediatric advance care planning (pACP) on the sustainability of end-of-life treatment preference congruence between adolescents with cancer and their families has not been examined.
HIV Preexposure Prophylaxis Among People With Substance Use Disorder—The Road Less Traveled
Authors: Ruchi Bhandari
Journal: JAMA Network Open (2022)

Carl G. Streed Jr, MD, MPH; Jake R. Morgan, PhD; Mam Jarra Gai, MPH; Marc R. Larochelle, MD, MPH; Michael K. Paasche-Orlow, MD, MPH; Jessica L. Taylor, MD
Error in Results and Table
Journal: JAMA Network Open (2022)

Letter titled, "Comparison of Screening Colonoscopy Rates After Positive Noninvasive Testing for Colorectal Cancer in States With and Without Cost-Sharing," 1 published June 14, 2022, there was an error in the Results and in Table 2.The 95% CI for the odds ratio of patients in Oregon receiving any colorectal cancer screening after policy implementation should have been listed as 1.00 to 1.12.This article has been corrected. 1
Error in Results
Journal: JAMA Network Open (2022)

Lilia Cervantes, MD; Cynthia A. Hazel, DrPH, MSc; Diana Mancini, MD; Rocio I. Pereira, MD; Laura J. Podewils, PhD; Sarah A. Stella, MD; Joshua Durfee, MSPH; Alana Barshney, MS; John F. Steiner, MD, MPH
An Economic Perspective on Platform Trials—The Gift and the Curse
Authors: Olivier Collignon
Journal: JAMA Network Open (2022)

Jay J. H. Park, PhD; Behnam Sharif, PhD; Ofir Harari, PhD; Louis Dron, MSc; Anna Heath, PhD; Maureen Meade, MD, MSc; Ryan Zarychanski, MD, MSc; Raymond Lee, MSc; Gabriel Tremblay, DBA; Edward J. Mills, PhD; Yannis Jemiai, PhD; Cyrus Mehta, PhD; J. Kyle Wathen, PhD
Sex-Specific Transmission of Anxiety Disorders From Parents to Offspring
Authors: Barbara Pavlova, Alexa Bagnell, Jill Cumby, Emily Howes Vallis, Sabina Abidi, David Lovas, Lukas Propper, Martin Alda, Rudolf Uher
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Although anxiety disorders are known to run in families, the relative contribution of genes and environment is unclear. Patterns of sex-specific transmission of anxiety may point to different pathways in how parents pass anxiety disorders down to their children; however, the association of parent and offspring sex with the transmission of anxiety disorders has not been previously studied. <h3>Objective</h3> To examine whether the transmission of anxiety from parents to children is sex specific. <h3>Design, Setting, and Participants</h3> This cross-sectional family study recruited participants from the general population (enriched for familial risk of mood disorders) in Nova Scotia, Canada, from February 1, 2013, to January 31, 2020. <h3>Exposures</h3> Anxiety disorder in the same-sex or opposite-sex parent. <h3>Main Outcomes and Measures</h3> Semistructured interviews were used to establish lifetime diagnoses of anxiety disorder in parents and offspring. The association between anxiety disorder in the same-sex or opposite-sex parent and anxiety disorders in the offspring was tested with logistic regression. <h3>Results</h3> A total of 398 offspring (203 female offspring with a mean [SD] age of 11.1 [3.7] years and 195 male offspring with a mean [SD] age of 10.6 [3.1] years) of 221 mothers and 237 fathers participated in the study. Anxiety disorders in the same-sex parent (odds ratio [OR], 2.85; 95% CI, 1.52-5.34;<i>P</i> = .001) were associated with increased rates of anxiety disorders in the offspring, whereas anxiety disorders in the opposite-sex parent (OR, 1.51; 95% CI, 0.81-2.81;<i>P</i> = .20) were not. Sharing a household with a same-sex parent without anxiety was associated with lower rates of offspring anxiety (OR, 0.38; 95% CI, 0.22-0.67;<i>P</i> = .001), but the presence of an opposite-sex parent without anxiety was not (OR, 0.96; 95% CI, 0.56-1.63;<i>P</i> = .88). <h3>Conclusions and Relevance</h3> In this cross-sectional study of families, an association between the same-sex parent's anxiety disorder and anxiety disorders in offspring suggests an environmental mechanism, such as modeling. Future studies should establish whether treating parents' anxiety may protect their children from developing an anxiety disorder.
Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use
Authors: Carl G. Streed, Jake R. Morgan, Mam Jarra Gai, Marc R. Larochelle, Michael K. Paasche-Orlow, Jessica L. Taylor
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Although HIV preexposure prophylaxis (PrEP) implementation among persons who inject drugs has been inadequate, national HIV monitoring programs do not include data on PrEP, and specific trends in PrEP use are not well understood. <h3>Objective</h3> To estimate HIV PrEP uptake among commercially insured persons with opioid or stimulant use disorder by injection drug use (IDU) status. <h3>Design, Setting, and Participants</h3> This cross-sectional study used deidentified data from the MarketScan Commercial Claims and Encounters Database to identify a sample of 547 709 commercially insured persons without HIV but with opioid and/or stimulant use disorder, including 110 592 with evidence of IDU between January 1, 2010, and December 31, 2019. Data were analyzed from November 1, 2020, to July 1, 2021. <h3>Exposures</h3> Persons with opioid and/or stimulant use disorder and evidence of IDU were identified through claims data. <h3>Main Outcomes and Measures</h3> The outcome was receipt of tenofovir disoproxil fumarate and emtricitabine for PrEP as identified from filled pharmacy claims. Multivariable logistic regression was used to assess the association of demographic and clinical characteristics with receipt of PrEP. <h3>Results</h3> The study cohort included 211 609 (28.6%) females and 336 100 (61.4%) males with a combined mean (SD) age of 34.8 (13.1) years, including 110 592 individuals with evidence of IDU. During the study period, 508 (0.09%) persons with opioid and/or stimulant use disorder, including 170 (0.15%) with evidence of IDU, received PrEP. Receipt of PrEP increased from 0.001 to 0.243 per 100 person-years from 2010 through 2019 among the entire cohort and from 0.000 to 0.295 per 100 person-years among those with IDU. In multivariable analysis, PrEP use was more likely among males (adjusted odds ratio [aOR] 8.72; 95% CI, 6.39-11.89), persons with evidence of IDU (aOR, 1.47; 95% CI, 1.21-1.79), and persons with evidence of sexual risk indications for PrEP (aOR, 23.68; 95% CI, 19.57-28.66). <h3>Conclusions and Relevance</h3> In this cross-sectional study of commercially insured persons with opioid and/or stimulant use disorder, HIV PrEP delivery remained low, including among those with evidence of IDU. PrEP should be consistently offered alongside substance use disorder treatment and other harm reduction and HIV prevention services.
Associations between low Apgar scores and mortality by race in the United States: A cohort study of 6,809,653 infants
Authors: Emma Gillette, James P. Boardman, Clara Calvert, Jeeva John, Sarah J. Stock
Journal: PLoS Medicine (2022)

Background Apgar scores measure newborn health and are strongly associated with infant outcomes, but their performance has largely been determined in primarily white populations. Given the majority of the global population is not white, we aim to assess whether the association between low Apgar score and mortality in infants varies across racial groups. Methods and findings Population-based cohort study using 2016 to 2017 United States National Vital Statistics System data. The study included singleton infants born between 37 +0 and 44 +6 weeks to mothers over 15 years, without congenital abnormalities. We looked at 3 different mortality outcomes: (1) early neonatal mortality; (2) overall neonatal mortality; and (3) infant mortality. We used logistic regression to assess the association between Apgar score (categorized as low, intermediate, and normal) and each mortality outcome, and adjusted for gestational age, sex, maternal BMI, education, age, previous number of live births, and smoking status, and stratified these models by maternal race group (as self-reported on birth certificates). The cohort consisted of 6,809,653 infants (52.8% non-Hispanic white, 23.7% Hispanic, 13.8% non-Hispanic black, 6.6% non-Hispanic Asian, and 3.1% non-Hispanic other). A total of 6,728,829 (98.8%) infants had normal scores, 63,467 (0.9%) had intermediate scores, and 17,357 (0.3%) had low Apgar scores. Compared to infants with normal scores, low-scoring infants had increased odds of infant mortality. There was strong evidence that this association varied by race ( p &lt; 0.001) with adjusted odds ratios (AORs) of 54.4 (95% confidence interval [CI] 49.9 to 59.4) in non-Hispanic white, 70.02 (95% CI 60.8 to 80.7) in Hispanic, 23.3 (95% CI 20.3 to 26.8) in non-Hispanic black, 100.4 (95% CI 74.5 to 135.4) in non-Hispanic Asian, and 26.8 (95% CI 19.8 to 36.3) in non-Hispanic other infants. The main limitation was missing data for some variables, due to using routinely collected data. Conclusions The association between Apgar scores and mortality varies across racial groups. Low Apgar scores are associated with mortality across racial groups captured by United States (US) records, but are worse at discriminating infants at risk of mortality for black and non-Hispanic non-Asian infants than for white infants. Apgar scores are useful clinical indicators and epidemiological tools; caution is required regarding racial differences in their applicability.